全球无针注射系统市场 – 行业趋势及 2029 年预测

市场分析和规模

无针注射系统是一项稳步发展的技术，有望使药物给药更加高效，减少疼痛。无针注射技术允许医生在不刺穿患者皮肤的情况下给患者注射药物。无针技术有许多优点，包括降低患者对使用针头的焦虑。无针注射非常有效，并且对于多种药物而言与注射器和针头注射具有生物等效性。它的疼痛阈值较低，深受患者青睐。与传统针头相比，注射速度更快，并且不存在针头处置困难。制药行业不仅可以从产品销售增长中受益，而且还有潜力提高对给药方案和结果的依从性。

Data Bridge Market Research 分析称，无针注射系统市场规模在 2021 年为 1.24 亿美元，到 2029 年将飙升至 4.661 亿美元，预计在 2022-2029 年预测期内的复合年增长率为 18.0%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

市场定义

无针注射系统是一种创新方法，无需用针刺穿患者皮肤即可为患者提供各种药物。无针技术具有明显的优势，可以最大限度地减少患者对使用针头的焦虑。无针注射技术是一个广泛的概念，涵盖了各种药物输送装置，这些装置利用洛伦兹、冲击波、气压或电泳等力量将药物通过皮肤推进，从而有效地消除了对皮下注射针头的需求。

Report Scope and Market Segmentation

Needle-Free Injection System Market Dynamics

Drivers

• High incidence of infectious diseases globally

Despite tremendous advancements in sanitation and medicine, infectious illness prevalence remains high over the world. Despite the fact that non-communicable diseases are the leading causes of morbidity and mortality, infectious diseases remain a serious public health concern around the world. According to the National Institute of Allergy and Infectious Diseases, infectious diseases claim the lives of more than 15 million people each year. Despite the fact that non-communicable diseases are the leading causes of morbidity and mortality, infectious diseases remain a serious public health concern around the world. According to the National Institute of Allergy and Infectious Diseases, infectious diseases claim the lives of more than 15 million people each year.

• Growing incidence of transmissible diseases

Most healthcare providers are concerned about needlestick injuries caused by infected needles. Needle stick injuries are most dangerous hazards to people’s health and safety. Because injections are one of the most commonly used procedures for administering pharmaceuticals, healthcare workers are at a high risk of contracting blood-borne diseases through needlestick injuries, which can happen by accident. Every year, some 385,000 health-care workers inadvertently poke themselves with needles, according to the CDC. Needlestick injuries can spread infectious diseases like hepatitis B, hepatitis C, and the human immunodeficiency virus (AIDS) to healthcare workers.

Increase in demand for self-injection devices

Self-injection technologies are a faster and more repeatable technique of providing pharmaceuticals than invasive drug administration methods. Self-injections lower medicine dosage requirements, resulting in improved patient compliance, particularly among the elderly.

• Increased number of technological developments

E- and prescription, and other new technology can assist doctors and pharmacists in a variety of ways, including storing professionals to deliver high-quality, effective medicines. It also helps patients comprehend the majority scheduled proceedings and data and smoothing immunisation progress. Information Technology (IT) has improved safety and patients health, allowing pharmaceutical industry specialists to better understand the effects of their products.

Opportunities

• Increasing demand for biosimilars and immunization procedures

Biosimilars are becoming more widely employed to treat diseases such as cancer, diabetes, hepatitis, anaemia, and a variety of other acute and chronic illnesses. The need for biosimilars is growing in tandem with the rising prevalence of these diseases. There is a substantial opportunity for pharmaceutical and medical device companies to create innovative biosimilar delivery options. Injections are used to provide a variety of biosimilars and vaccines; in this case, needle-free technology provides an easy-to-use and safe method of giving biosimilars without the requirement for a standard injection apparatus or trained people.

• Increasing number of emerging markets

In the future years, the needle-free injection system market in emerging countries is predicted to rise significantly. This is due to an increase in the prevalence of chronic diseases, strong economic growth, and rising purchasing power. The presence of numerous individuals suffering from chronic diseases and the availability of competent labour at a reduced cost characterise growing economies such as India and China.

Restraints/Challenges

• Higher cost of development as associated to conventional injection systems

The complexity of these gadgets increases development expenses. The high cost of units is a result of the significant investment in development, which reduces patient acceptance of these devices. Due to additional associated expenditures such as high infrastructural and personnel costs, the overall development cost of a needle-free injection system is significantly greater.

• Sterilizable needles and conventional needle injections

Needle-free injections, need significant upfront investments and are expected to be more expensive as manufacturers spends more on quality control and device production standards. Needle-free injection starter kits from AdvantaJet, Injex 30, and Medi-Jector cost around USD 165, 260, and 300, respectively. Because needle-free injection devices are more expensive than typical needle injections, their affordability becomes a major challenge.

This needle-free injection system market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the needle-free injection system market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Needle-Free Injection System Market

In the most hopeful scenario, the COVID-19 epidemic has had a favorable impact on the needle-free injection system market as a whole. The COVID-19 pandemic has had a favorable impact on the needle-free injection system market, as the necessity for mass vaccination and self-injectable devices has been a priority since the epidemic began in December 2019. As the number of instances has grown across the globe, the majority of the leading needle-free injection system market players have invested in RandD and formed collaborations and agreements with other industry players and government agencies to create a needle-free injection system for the condition.

Recent Development

• In December 2021, Nykode Therapeutics, a PharmaJet partner, will launch a phase 1/2 clinical study using next-generation DNA-based COVID-19 vaccine candidates. PharmaJet, a company that develops needle-free injection technology, announced today that Nykode Therapeutics (previously Vaccibody), one of its pharmaceutical partners, has started a phase 1/2 clinical trial to address developing SARS-CoV-2 variations. In the clinical trial, the DNA-based vaccinations will be administered intramuscularly only utilizing the PharmaJet Stratis Needle-free Injection System.
• In August 2021, Zydus Cadila, a PharmaJet partner, has received Emergency Use Authorization for the world's first plasmid DNA COVID-19 vaccination delivered via needle-free injection. PharmaJet, a pioneer in needle-free injection technology, said today that Zydus Cadila, one of its partners, has acquired an Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world's first Plasmid DNA Vaccine for COVID-19. The ZyCoV-D vaccination is only available through the PharmaJet Tropis Needle-free Injection System.

Global Needle-Free Injection System Market Scope

The needle-free injection system market is segmented on the basis of type, product, and technology, source of power, usability, delivery site, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Liquid-Based Needle-Free Injectors
• Projectile/Depot-Based Needle-Free Injectors
• Powder-Based Needle-Free Injectors

Product

• Fillable Needle-Free Injectors
• Prefilled Needle-Free Injectors

Technology

• Jet-Based Needle-Free Injectors
• Spring-Based Needle-Free Injectors
• Laser-Powered Needle-Free Injectors
• Vibration-Based Needle-Free Injectors

Source of Power

• Spring-Based Needle-Free Injectors
• Gas Propelled/ Air Forced Injector Systems

Usability

• Disposable Needle-Free Injectors
• Reusable Needle-Free Injectors

Delivery Site

• Subcutaneous Injectors
• Intramuscular Injectors
• Intradermal Injectors

Application

• Vaccine Delivery
• Insulin Delivery
• Oncology
• Pain Management
• Others

End-User

• Hospitals
• Clinics
• Home Care Settings
• Research Laboratories
• 制药和生物技术公司
• 其他的

无针注射系统市场区域分析/见解

对无针注射系统市场进行了分析，并按国家、类型、产品、技术、动力来源、可用性、交货地点、应用和最终用户提供了市场规模洞察和趋势。

无针注射系统市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

癌症和糖尿病等慢性病的发病率不断上升，北美占据了全球无针注射系统市场的最大份额。此外，患者对通过无针注射自行给药的需求日益增长，推动了该地区市场的发展。

由于患者对创新技术的倾向性增加，以及对生物制剂和无针注射药物自我给药的需求不断增长，预计亚太地区将在 2022-2029 年的预测期内迅速发展。此外，该地区市场将受益于增加投资以加强该地区的医疗保健支出，以及增加研发业务以生产更现代的无针方法以实现正确有效的药物给药。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

无针注射系统市场还为您提供每个国家/地区资本设备医疗保健支出增长、无针注射系统市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗保健监管情景的变化及其对无针注射系统市场的影响的详细市场分析。数据涵盖 2010-2020 年的历史时期。

竞争格局和无针注射系统市场份额分析

无针注射系统市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对无针注射系统市场的关注有关。

无针注射系统市场的一些主要参与者包括：

• Antares Pharma（美国）
• INOVIO Pharmaceuticals（美国）
• 国家医疗产品有限公司（沙特阿拉伯）
• Valeritas, Inc.（丹麦）
• InsuJet（荷兰）
• PenJet（荷兰）
• Amico 集团 (阿联酋)
• MedImmune（美国）
• Mystic Pharmaceuticals（美国）
• OptiNose US, Inc.（美国）
• Zogenix（美国）
• PharmaJet（美国）
• Portal Instruments（美国）
• 医疗国际技术公司（MIT）（美国）
• NuGen 医疗器械（加拿大）
• Crossject SA（美国）
• Bioject Medical Technologies（美国）

SKU-47757